Literature DB >> 10889387

Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization.

J Seong1, H C Park, K H Han, D Y Lee, J T Lee, C Y Chon, Y M Moon, C O Suh.   

Abstract

PURPOSE: The purpose of this study was to investigate the efficacy of local radiotherapy (RT) as a salvage treatment for unresectable hepatocellular carcinoma (HCC) patients who failed with transcatheter arterial chemoembolization (TACE). METHODS AND MATERIALS: Patients with unresectable HCC who had been treated with and eventually failed with TACE were eligible. The judgment of TACE failure was based on incomplete tumor filling of lipiodol-adriamycin mixture on either angiography or computed tomography (CT) scan. From January 1993 to December 1997, 27 patients were entered into this study. They had UICC Stage III (17) or IVA (10) disease, with a mean tumor size of 7.2 +/- 2.9 cm. Local RT was done, with a mean tumor dose of 51.8 +/- 7.9 Gy, in daily 1.8-Gy fractions using a 10- or 6-MV linear accelerator. Survival was calculated from both the diagnosis and the start of RT using the Kaplan-Meier method.
RESULTS: An objective response was observed in 16 of 24 patients (66.7%) including 1 CR. Intrahepatic metastasis was noted outside the RT field in 10 patients (37.0%). Extrahepatic distant metastasis occurred in 4 patients. Survival rates at 1, 2, and 3 years were 85. 2%, 58.1%, and 33.2%, respectively, from the diagnosis and 55.9%, 35. 7%, and 21.4%, respectively, from the start of RT. The median survivals were 26 months from the diagnosis and 14 months from the start of RT. Acute toxicity involved alteration in liver function test (13 patients) and thrombocytopenia (2 patients). Subacute and chronic toxicity involved gastroduodenal ulcer (3 patients) and duodenitis (2 patients). There was no treatment-related death.
CONCLUSION: In unresectable HCC patients who failed with TACE, local RT induced a substantial tumor response of 66.7%, with a 3-year survival rate of 21.4% and a median survival time of 14 months. Toxicity was significant but manageable. Although we do not know if there is survival benefit through this treatment, local RT in these patients seems to be valuable as a salvage for TACE-failed HCC.

Entities:  

Mesh:

Year:  2000        PMID: 10889387     DOI: 10.1016/s0360-3016(00)00519-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  33 in total

1.  Radiation therapy for portal venous invasion by hepatocellular carcinoma.

Authors:  Keiichi Nakagawa; Hideomi Yamashita; Kenshiro Shiraishi; Naoki Nakamura; Masao Tago; Hiroshi Igaki; Yoshio Hosoi; Shuichiro Shiina; Masao Omata; Masatoshi Makuuchi; Kuni Ohtomo
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

2.  Hepatic lesion radiotherapy: a new option? Interview by Paul Adams.

Authors:  Michael Lock
Journal:  Can J Gastroenterol       Date:  2008-07       Impact factor: 3.522

Review 3.  Radiotherapy for liver tumors.

Authors:  Florence K Keane; Shyam K Tanguturi; Andrew X Zhu; Laura A Dawson; Theodore S Hong
Journal:  Hepat Oncol       Date:  2015-04-20

4.  Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.

Authors:  Roderich E Schwarz; Ghassan K Abou-Alfa; Jeffrey F Geschwind; Sunil Krishnan; Riad Salem; Alan P Venook
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

Review 5.  Combined interventional therapies of hepatocellular carcinoma.

Authors:  Jun Qian; Gan-Sheng Feng; Thomas Vogl
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

6.  Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.

Authors:  De-Hua Wu; Li Liu; Long-Hua Chen
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

Review 7.  Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma.

Authors:  Chihwan Choi; Gi Hong Choi; Tae Hyun Kim; Masatoshi Tanaka; Mao-Bin Meng; Jinsil Seong
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

8.  Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer.

Authors:  Jung Hyun Kwon; Si Hyun Bae; Ji Yoon Kim; Byung Ock Choi; Hong Seok Jang; Jeong Won Jang; Jong Young Choi; Seung Kew Yoon; Kyu Won Chung
Journal:  BMC Cancer       Date:  2010-09-03       Impact factor: 4.430

Review 9.  Challenge and hope in radiotherapy of hepatocellular carcinoma.

Authors:  Jinsil Seong
Journal:  Yonsei Med J       Date:  2009-10-20       Impact factor: 2.759

10.  Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma.

Authors:  Wei-Jian Guo; Er-Xin Yu; Lu-Ming Liu; Jie Li; Zhen Chen; Jun-Hua Lin; Zhi-Qiang Meng; Yi Feng
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.